Top-News
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing
PHILADELPHIA, Nov. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").
Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
Telix, headquartered in Melbourne, Australia, is a biopharmaceutical company developing diagnostic and therapeutic radiopharmaceutical products.
During the Class Period, defendants allegedly made false or misleading statements and/or failed to disclose that the Company had overstated its progress with prostate cancer therapeutic candidates and exaggerated the quality of its supply chain and partners. As a result, statements regarding the Company's business, operations, and prospects were allegedly false, misleading, or lacked a reasonable basis. According to the complaint, when the true state of the Telix's business became public, investors suffered significant losses.
If you are a Telix investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Director of Portfolio & Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigating-claims-on-behalf-of-telix-pharmaceuticals-ltd-nasdaq-tlx-after-class-action-filing-302613242.html
SOURCE Berger Montague
Für dich aus unserer Redaktion zusammengestellt
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.